Ann: Bod commences import of cannabis products, page-8

Fluctuations in price shouldn't be of concern if fundamentals are good, I am long on BOD, it has short term prospects that others lack: a possibly positive cash flow is achievable this year, a commercial footprint in China with an experienced sales team (ex Bellamy) and a fast tracked Phase I clinical study taking shape that could see a licensing agreement following release of good data.
If the sp keeps deeping I will buy some more.